Gregg Gilbert
Stock Analyst at Truist Securities
(2.25)
# 2,779
Out of 5,006 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.62 | +46.30% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $33.83 | +9.37% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $45.14 | +86.09% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $845.05 | -37.87% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.43 | +102.18% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $14.50 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $88.80 | +4.73% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $19.76 | +142.91% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.70 | +1,429.41% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $1.94 | +7,631.96% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $22.05 | +253.74% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $145.36 | -46.34% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $19.96 | -9.82% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $137.58 | +27.20% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $230.19 | -71.33% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.62
Upside: +46.30%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $33.83
Upside: +9.37%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $45.14
Upside: +86.09%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $845.05
Upside: -37.87%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.43
Upside: +102.18%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $14.50
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $88.80
Upside: +4.73%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $19.76
Upside: +142.91%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.70
Upside: +1,429.41%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $1.94
Upside: +7,631.96%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $22.05
Upside: +253.74%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $145.36
Upside: -46.34%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $19.96
Upside: -9.82%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $137.58
Upside: +27.20%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $230.19
Upside: -71.33%